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Objectives: Rapid Virologic Response (RVR) is currently used as the best predictor 
of Sustained Virologic Response (SVR) with dual therapy (DT) in genotype-1 chronic 
hepatitis C (G1-CHC), to optimize the adoption of the triple therapy (TT) with 
direct-acting antivirals (boceprevir: BOC and telaprevir: TVR). Bio-mathematical 
modelling of viral dynamics during DT has potentially higher accuracy than RVR 
in the identification of SVR patients. The objective of this study was to analyse 
the cost-effectiveness profile of a personalized anti-HCV therapy in F0-F2 G1-CHC 
based on a bio-mathematical model (model-guided strategy: MG) rather than on 
the RVR (guideline-guided strategy: GG). MethOds: A deterministic bio-math-
ematical model of the infected cell dynamics was validated in a cohort of 135 
G1-CHC patients treated with DT at the University Hospital in Pisa, Italy. A lifetime 
health economic (HE) model was then developed to compare MG and GG strategies 
in the perspective of the Italian National Health Service. The model was alimented 
with observed data in the validation cohort, clinical variables and economic 
data available in the literature. A 3.5% discount rate was applied to outcomes 
and costs. One-way and probabilistic sensitivity analyses were run. Results: 
The outcomes with MG- and GG-strategy were 19.1-19.4 and 18.9-19.3 quality-
adjusted-life-years (QALY). Total per-patient lifetime costs were € 25,200-€ 26,000 
with MG-strategy and € 28,800-€ 29,900 with GG-strategy. When comparing MG- 
with GG-strategy the former resulted more effective and less costly, being defined 
as dominant. cOnclusiOns: The adoption of a SVR predictive criterion based 
on a bio-mathematical model, has the potential to improve the cost-effectiveness 
of a personalized anti-HCV therapy, allowing a more accurate identification of 
patients who can be effectively treated with DT and reserving high-cost BOC- and 
TVR-based TT for those who really need it.
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Objectives: Pegylated interferon-α plus ribavirin (PR) has been the standard of 
care for Chronic Hepatitis C (CHC). Therapy adding boceprevir (BOC) or telaprevir 
(TVR) to PR in HCV genotype-1 patients has failed to achieve generalized market 
acceptance, in part due to the approval of newer more efficacious and safer options 
like sofosbuvir (SOF), a new pan-genotypic RNA-polymerase inhibitor. Objective: To 
assess the cost-effectiveness of sofosbuvir based therapy for CHC across HCV geno-
types, pretreatment conditions and HIV co-infection in Portugal. MethOds: Costs 
and effectiveness were estimated based on discrete-time Markov-type model for 
CHC evolution accounting for different subpopulations in terms of HCV genotype, 
fibrosis progression, HIV co-infection status and previous treatment experience. 
The model incorporates 13 health states: 5 Metavir score, 2 SVR (with and without 
cirrhosis) and 3 advanced liver disease states (decompensated cirrhosis, hepatocel-
lular carcinoma, liver transplant). Results are expressed in incremental costs per 
life year (LY) and quality-adjusted life year (QALY). Results: Overall sofosbuvir-
containing regimens are expected to result in an increment of 3.49 LY (3.05 QALY) 
after weighting for the different subpopulations assuming Portuguese epidemiol-
ogy. The corresponding weighted incremental cost-effectiveness ratios (ICER) was 
14,649€ /LY (16,720€ /QALY). In the comparison against the BOC and TVR containing 
regimens (genotype-1), ICER of 10,675€ /LY (12,238€ /QALY) and 14,618€ /LY (16,495€ /
QALY) were obtained, respectively. For HIV co-infected and PegIFN eligible/tolerant 
patients, estimated ICER varied between 6,463€ /LY (6,902€ /QALY) and 21,281€ /LY 
(28,245€ /QALY), for G1 and G2, respectively, when comparing against treatment with 
PR. Additionally, in HCV/HIV coinfected patients ineligible/intolerant to PegIFN, the 
comparison against lack-of-therapy resulted in ICER of 15,656€ /LY (17,756€ /QALY) 
and 12,915€ /LY (19,077€ /QALY), for HCV G1 and G3, respectively. cOnclusiOns: 
Sofosbuvir-containing regimens for the treatment of adult CHC patients, irrespec-
tive of HIV co-infection status, are expected to result in significant health gains at 
an incremental cost within the range of European Health Authorities acceptability.
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Objectives: To evaluate the clinical and economic expediency of adding simeprevir 
(SMV) to pegylated-interferon and ribavirin (PR) versus PR only, or triple thera-
pies with PR plus boceprevir (BOC) or telaprevir (TVR) for treatment of genotype 
1 chronic hepatitis C (CHC) virus infection in patients who have failed previous 
therapy with interferon and ribavirin in Russia. MethOds: A Markov model devel-
oped earlier was adapted to the Russian settings. The analysis consists of 2 time 
periods: 1st the antiviral therapy (AVT) phase and 24 week follow-up (0-72 weeks) 
and 2ndthe disease progression of CHC (72 weeks - lifetime). Incidences of disease 
progression health-states (decompensated cirrhosis, hepatocellular carcinoma, liver 
transplant, post-liver transplant and death, associated with high health care costs, 
high mortality rates) based on available published data. Costs and outcomes (life 
years, LY) were analyzed for treatment experienced CHC patients from Russian 
health care system perspective. The incremental cost-effectiveness ratio (ICER) per 
Objectives: To estimate health care costs of alternative therapeutic strategies: 
no treatment versus peginterferon and ribavirin (PR) versus protease inhibi-
tor (PI) boceprevir added to PR for Russian treatment experienced chronic HCV 
patients, who had failure previous treatment, in short- and long-term time hori-
zon. MethOds: An Excel-based model was developed to evaluate costs and 
outcomes of chronic HCV treated with dual therapy with PR and triple therapy 
with boceprevir in combination with PR. Costs for two time periods were ana-
lysed: antiviral therapy costs (0-48 weeks) and disease-progression related costs 
(from 48 weeks to 25 years), depending on the chosen therapy. Antiviral drug costs 
were calculated on the base of registered prices from the list of vital and essential 
drugs. Incidence of compensated and decompensated cirrhosis, hepatocellular 
carcinoma, liver transplant and post-liver transplant in the outcome of chronic 
HCV in long-term period was derived from available published data. Treatment 
costs of liver disease progression events were estimated according to the tariffs 
of the Russian health care system in 2014. Results: Boceprevir +PR compared 
to no treatment strategy and PR therapy was associated with more avoided 
liver-disease progression events at lesser costs, resulting in boceprevir+PR as 
the dominant treatment option in patients with chronic HCV genotype 1 non-
responders to previous treatment in Russia. Additional costs per avoided event of 
liver-disease progression for boceprevir plus PR and dual PR therapy were € 
12,654.26 and € 45,082.82 respectively. cOnclusiOns: Antiviral therapy with 
boceprevir plus PR in comparison with only PR therapy and no treatment strat-
egy is cost effective due to reduced frequency of disease progression events and 
associated costs.
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Objectives: The clinical efficacy of lubiprostone in chronic idiopathic constipa-
tion has been demonstrated in three randomised clinical trials (RCTs). This analy-
sis assesses the cost effectiveness of lubiprostone compared to prucalopride (the 
current standard of care), placebo and immediate referral to secondary care from 
the perspective of the UK National Health Service (NHS). MethOds: A state-
transition model was constructed to represent the treatment pathway for chronic 
idiopathic constipation from an NHS perspective with a 1-year time horizon. The 
model considered treatment continuation rules, at Week 2 for lubiprostone and 
Week 4 for prucalopride. Clinical data were taken from RCTs and an indirect com-
parison with prucalopride. Long-term duration of treatment was estimated by fit-
ting curves to open-label study data. Costs included drug costs, medical resource 
use, and the cost of the pathway including primary and secondary care, obtained 
from published sources. Quality of life was modelled according to whether con-
stipation was resolved or unresolved, with values taken from a large published 
study (n= 1,200). Results: Compared to placebo, lubiprostone delayed referral to 
secondary care and improved quality of life, but resulted in increased costs due to 
treatment, the incremental cost-effectiveness ratio was £2,924. Lubiprostone and 
prucalopride were found to have similar efficacy, with lubiprostone generating an 
additional 0.0014 QALYs in the base case. The cost per day for lubiprostone is lower 
than for prucalopride; leading to lower total costs (£1,596 v £1,655), and meaning 
lubiprostone dominated prucalopride (lower cost and higher QALYs). Probabilistic 
sensitivity analysis showed lubiprostone to have an 84% chance of being the 
most cost-effective treatment at a threshold of £20,000 per QALY. cOnclusiOns: 
Treatment with lubiprostone provides substantial value to both patients and the 
NHS, being highly cost effective compared to placebo and dominant compared to 
the current standard of care.
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Objectives: Constipation-predominant irritable bowel syndrome (IBS-C) affects 
more than 2% of the population carrying a heavy burden in developed countries 
and leading to significant losses in patients’ quality of life. Treatment goals are 
to provide relief of abdominal pain, restore the bowel transit and alleviate associ-
ated symptoms. Linaclotide has been shown to significantly improve abdominal 
and bowel symptoms in two phase III trials being the only EMA approved therapy 
indicated for the treatment of IBS-C. Therefore, this study aimed to perform a 
cost-effectiveness analysis comparing linaclotide with no active treatment for 
the treatment of IBS-C from the Portuguese societal perspective. MethOds: A 
Markov model was developed to simulate the natural course and treatment of the 
disease. Patient-level satisfaction data from linaclotide’s randomised clinical trials 
was used to define 4 health states: ‘Not Satisfied’, ‘Moderately Satisfied’, ‘Satisfied’ 
and ‘Dead’. These data were linked to utility scores based on patients’ responses 
to the EuroQol-5D questionnaire. Transitions between health states were assumed 
to occur every 4 weeks, with probabilities derived from observed efficacy data 
up to 20-weeks. Extrapolation beyond this period was based on last observation 
carried forward data. Effectiveness was measured in quality-adjusted life years 
(QALY). Only direct costs were incorporated. Resource utilization was estimated 
from a literature review. Unit costs came from official Portuguese databases and 
pricing lists. Time horizon was fixed at 10 years. Probabilistic sensitivity analy-
sis was conducted with Monte Carlo simulations. Results: A mean gain of 0.22 
QALY (95%CI: [0.1; 0.35]) was estimated for each patient treated with linaclotide 
versus no treatment. Additionally, linaclotide utilization led to an overall aver-
age cost reduction of 402€ (95%CI: [-1,735; 536]) thus representing a dominant 
option. cOnclusiOns: When compared with no active treatment, linaclotide 
is a cost-saving and more effective therapeutic option for the treatment of IBS-C 
from the Portuguese societal perspective.
